Bupropion is the Antidepressant of Choice for Male Patients Concerned About Sexual Side Effects
For a male patient with depression who needs medication without sexual side effects, prescribe bupropion as first-line therapy. Bupropion has a significantly lower rate of sexual adverse events compared to SSRIs like fluoxetine and sertraline 1, 2.
Evidence-Based Rationale
The American College of Physicians guidelines explicitly state that bupropion had a significantly lower rate of sexual adverse events than fluoxetine or sertraline 1. This finding is consistent across multiple guideline statements and represents the strongest evidence available for antidepressant selection when sexual function is a priority.
Comparative Sexual Dysfunction Rates
Among second-generation antidepressants:
- Lowest risk: Bupropion (comparable to placebo) 3
- Intermediate risk: Fluoxetine, fluvoxamine, nefazodone, sertraline
- Highest risk: Paroxetine (higher rates of sexual dysfunction than fluoxetine, fluvoxamine, nefazodone, or sertraline) 1
- Also low risk: Mirtazapine shows modestly lower risk compared to citalopram 4
Recent observational data from Denmark involving over 300,000 treatment episodes confirms that mirtazapine demonstrated modest evidence of a lower risk relative to citalopram (HR 0.87), while venlafaxine showed the highest risk 4.
Alternative Options
If bupropion is contraindicated or not tolerated:
- Mirtazapine: Lower sexual side effect profile than SSRIs 4, 3, though associated with weight gain and sedation 1
- Agomelatine: Similar to placebo regarding sexual dysfunction 3, though availability varies by region
- Reboxetine: Selective noradrenaline reuptake inhibitor with sexual function profile similar to placebo and superior to fluoxetine 5
Critical Caveats
Bupropion-Specific Warnings
- Contraindicated in patients with seizure disorders or conditions that increase seizure risk 1
- Weak evidence suggests bupropion may be associated with increased seizure risk 1
- Should not be used in highly agitated patients 6
- Tends to be activating, which can be beneficial for apathetic depression but problematic for anxious presentations
SSRIs to Avoid
Paroxetine should be specifically avoided in patients concerned about sexual function, as it has the highest rates of sexual dysfunction among second-generation antidepressants 1, 2.
Clinical Implementation
When prescribing bupropion for this patient:
- Start with 37.5 mg every morning, increase by 37.5 mg every 3 days 6
- Maximum dose: 150 mg twice daily
- Give second dose before 3 PM to minimize insomnia risk 6
- Monitor for rapid improvement in energy level (can occur quickly)
- Assess response within 6-8 weeks; modify treatment if inadequate response 1
Monitoring Requirements
Begin monitoring within 1-2 weeks of initiation for therapeutic response and adverse effects 1. This is particularly important given the FDA warning about monitoring for increased suicidal thoughts and behaviors with all antidepressants, especially during the first 1-2 months of treatment 1.
Important Context
Sexual dysfunction is significantly underreported in clinical trials 1, meaning the true rates are likely higher than published data suggest. Proactively discussing sexual side effects before medication selection improves treatment adherence and patient satisfaction 7.
All second-generation antidepressants have equivalent efficacy for treating major depressive disorder 1, so selection should be based on adverse effect profiles, cost, and patient preferences 1. Since this patient has specifically identified sexual function as a priority, bupropion's superior profile in this domain makes it the clear first choice.